For research use only. Not for therapeutic Use.
FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 can be used for the research of cancer[1].
FX-909 (0.03-1 mg/kg; BID for 21 days) shows anticancer effects in UMUC9 UC xenograft mouse model[1].
| Catalog Number | I041367 |
| CAS Number | 2924573-90-8 |
| Synonyms | 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile |
| Molecular Formula | C17H10F2N2O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C17H10F2N2O3S/c1-25(23,24)16-3-2-9(8-20)4-11(16)13-7-15(22)17-12(19)5-10(18)6-14(17)21-13/h2-7H,1H3,(H,21,22) |
| InChIKey | RBUBBZVQPHSZEZ-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)C1=C(C=C(C=C1)C#N)C2=CC(=O)C3=C(N2)C=C(C=C3F)F |
| Reference | [1]. Mertz J A, et al. Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG). Cancer Research, 2023, 83(7_Supplement): 2802-2802. |
